Suppr超能文献

威尔逊氏病最新进展:印度视角

Wilson's Disease Update: An Indian Perspective.

作者信息

Kumar Niraj, Prashant L K, Goyal Vinay

机构信息

Department of Neurology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.

Center for Parkinson's Disease and Movement Disorders, Vikram Hospital, Bengaluru, Karnataka, India.

出版信息

Ann Indian Acad Neurol. 2021 Sep-Oct;24(5):652-663. doi: 10.4103/aian.AIAN_171_21. Epub 2021 Oct 14.

Abstract

Wilson's disease (WD) is an autosomal recessive disorder due to ATP7B gene mutation, resulting in defective copper metabolism, with the liver and brain being primarily affected. WD being a treatable disorder, early diagnosis and proper management may result in near complete recovery. It has received significant attention over the past 50 years, with several Indian contributions. This study collates published Indian studies on WD in Pubmed and Embase databases and puts them in perspective. Several Indian case series suggest WD may be more prevalent than thought. Commonly detected ATP7B mutation in India is p.C271X. Although initial Indian series reported significant osseomuscular presentation, neuropsychiatric and hepatic manifestations dominated the later reports. A significant male predominance is observed in the Indian series. Pure hepatic presentation starts earlier than neurological or osseomuscular WD. A positive family history may be seen in nearly 50% of Indian WD cases, with a high rate of consanguinity. Up to two-third of the Indian cases may be initially misdiagnosed, with a mean diagnostic delay of up to 2 years. Abnormalities in serum ceruloplasmin and 24-hour urinary copper has been reported in more than four-fifth cases. Brain MRI is abnormal in nearly all neurological WD cases. Copper chelation remains the mainstay of therapy, with D-penicillamine being the most widely used chelator in India. Global Assessment Scale for WD is a comprehensive tool for clinical monitoring. Hepatic presentation carries a five-time higher mortality risk than neurological, with up to 90% Indian neurological WD cases recovering back to pre-morbid functionality with adequate therapy.

摘要

威尔逊病(WD)是一种常染色体隐性疾病,由ATP7B基因突变引起,导致铜代谢缺陷,主要影响肝脏和大脑。WD是一种可治疗的疾病,早期诊断和适当管理可能会带来近乎完全的康复。在过去50年里,它受到了广泛关注,印度也有多项相关贡献。本研究整理了在Pubmed和Embase数据库中发表的关于WD的印度研究,并对其进行了分析。几个印度病例系列表明,WD可能比人们想象的更普遍。印度常见的ATP7B突变是p.C271X。尽管最初的印度系列报道了明显的骨肌肉表现,但后来的报道中神经精神和肝脏表现占主导地位。在印度系列中观察到明显的男性优势。单纯肝脏表现比神经或骨肌肉性WD发病更早。近50%的印度WD病例可能有阳性家族史,近亲结婚率很高。多达三分之二的印度病例最初可能被误诊,平均诊断延迟长达2年。超过五分之四的病例报告了血清铜蓝蛋白和24小时尿铜异常。几乎所有神经型WD病例的脑部MRI都有异常。铜螯合仍然是主要治疗方法,D-青霉胺是印度使用最广泛的螯合剂。WD全球评估量表是临床监测的综合工具。肝脏表现的死亡风险比神经型高五倍,多达90%的印度神经型WD病例通过适当治疗可恢复到病前功能状态。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c3e/8680915/1babf232f0fc/AIAN-24-652-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验